These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 15879092)

  • 1. Multiple costimulatory modalities enhance CTL avidity.
    Hodge JW; Chakraborty M; Kudo-Saito C; Garnett CT; Schlom J
    J Immunol; 2005 May; 174(10):5994-6004. PubMed ID: 15879092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
    Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
    J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
    Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
    Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen.
    Hernández J; Ko A; Sherman LA
    J Immunol; 2001 Mar; 166(6):3908-14. PubMed ID: 11238635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective induction of high avidity CTL by altering the balance of signals from APC.
    Oh S; Hodge JW; Ahlers JD; Burke DS; Schlom J; Berzofsky JA
    J Immunol; 2003 Mar; 170(5):2523-30. PubMed ID: 12594278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines.
    Rice J; Elliott T; Buchan S; Stevenson FK
    J Immunol; 2001 Aug; 167(3):1558-65. PubMed ID: 11466377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
    Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
    Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
    Ji Q; Gondek D; Hurwitz AA
    J Immunol; 2005 Aug; 175(3):1456-63. PubMed ID: 16034082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.
    Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    J Immunol; 2002 Nov; 169(10):5780-6. PubMed ID: 12421958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines with enhanced costimulation maintain high avidity memory CTL.
    Yang S; Hodge JW; Grosenbach DW; Schlom J
    J Immunol; 2005 Sep; 175(6):3715-23. PubMed ID: 16148117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
    Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
    J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
    Yang S; Linette GP; Longerich S; Haluska FG
    J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses.
    Chakraborty M; Schlom J; Hodge JW
    Cancer Immunol Immunother; 2007 Sep; 56(9):1471-84. PubMed ID: 17318654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
    Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
    J Immunol; 2003 Mar; 170(6):2912-22. PubMed ID: 12626542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
    Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
    Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.